Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Recruiting

Phase 2

Aztreonam & AvibactamStudy of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Sponsor:

Pfizer

Code:

NCT05639647

Conditions

Gram-negative Bacterial Infections

Eligibility Criteria

Sex: All

Age: 0 - 17

Healthy Volunteers: Not accepted

Interventions

ATM-AVI

BAT

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-11. This information was provided to ClinicalTrials.gov by Pfizer on 2025-10-02.